Microbiome JPM 2026: Novo Nordisk’s Jacob Peterson on the Future of Obesity TherapeuticsBy adminJanuary 24, 20260 Novo Nordisk is doubling down on obesity and diabetes. Speaking with Inside Precision Medicine at the 2026 J.P. Morgan Healthcare…
Longevity Novo Nordisk’s Alzheimer’s GLP-1 gamble failsBy adminNovember 26, 20250 Long shot Phase 3 trial finds semaglutide did not deliver a statistically significant reduction in Alzheimer’s progression. Pharma giant Novo…
Microbiome Novo Nordisk’s GLP-1 Drug Fails to Improve Alzheimer’s SymptomsBy adminNovember 25, 20250 Credit: Juan Gaertner/Science Photo Library/Getty Images The results from two Phase III trials announced this week show Novo Nordisk’s GLP-1…
DNA & Genetics Analysts See Pain, and Necessity, in Novo Nordisk’s 9,000 LayoffsBy adminSeptember 14, 20250 Novo Nordisk (NASDAQ Copenhagen: NOVO-B) inflicted much pain—and much-needed pain—on the company when president and CEO Maziar (Mike) Doustdar announced…
